Loading...
Market
Will Kailera Therapeutics secure FDA approval for its first obesity treatment by December 31, 2024?
2
Kailera Therapeutics•Hercules CM NewCo•Ron Renaud•Atlas Venture•Bain Capital Life Sciences•RTW Investments
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and Kailera Therapeutics press releases
Story
Kailera Therapeutics Raises $400M in Series A Financing for Obesity Treatments, Ron Renaud as CEO
Oct 1, 2024, 11:30 AM
Kailera Therapeutics, an obesity treatment developer, has raised $400 million in a Series A financing round. The startup, previously known as 'Hercules CM NewCo,' is led by CEO Ron Renaud, who has a track record of successful acquisitions. The funding round, announced on Tuesday, was backed by Atlas Venture, Bain Capital Life Sciences, and RTW Investments. This significant investment underscores the competitive nature of the obesity drug market, with Kailera Therapeutics aiming to advance its portfolio of next-generation therapies for obesity and related conditions. The company is already striking a deal for commercial manufacturing.
View original story
Similar markets
Approved • 25%
Conditionally approved • 25%
Not approved • 25%
Approval pending • 25%
Yes • 50%
No • 50%
Exceeds expectations • 25%
Meets expectations • 25%
Falls short of expectations • 25%
Trial cancelled • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
